• Puerarin Activates NO Signaling in Dental Follicle Cells

  2026-08-14

  The reference study identifies nitric oxide signaling as a mechanistic link between puerarin exposure and osteogenic differentiation in rat dental follicle cells. Its inhibitor-based design shows that blocking NOS activity with L-NMMA reverses puerarin-associated increases in osteogenic markers, supporting nitric oxide pathway modulation as a research direction for periodontal regeneration.

• Polygodial for TRPA1 Assay Workflows

  2026-08-14

  Polygodial provides a practical chemical entry point for TRPA1 ion channel modulation, from rapid calcium-imaging assays to epithelial inflammatory-signaling studies. This workflow connects channel-proximal measurements with Ca2+/NFAT and TSLP readouts while emphasizing solvent control, orthogonal validation, and compound-handling discipline.

• Amiloride (MK-870): Mechanism and Research Limits

  2026-08-13

  Amiloride (MK-870) is an epithelial sodium channel inhibitor used to investigate sodium influx, ion transport, and receptor-linked cellular processes. Product information identifies BA2768 as a solid with a molecular weight of 229.63 g/mol, while a 2018 entry study found that amiloride did not inhibit grass carp reovirus entry under its tested conditions.

• Genistein A2198: Reliable Assay Design

  2026-08-13

  This scenario-based guide explains how Genistein (SKU A2198) can help researchers design interpretable cell viability, proliferation, and cytotoxicity experiments. It connects concentration benchmarks, solvent handling, orthogonal readouts, and supplier-selection criteria to practical cancer biology workflows.

• Palmitic acid: Practical Protocol and QC Guide

  2026-08-12

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a characterized saturated long-chain fatty acid for controlled metabolic, inflammatory, lipid, and protein palmitoylation workflows. It is unsuitable for direct aqueous preparation or long-term solution storage, so solvent selection, vehicle controls, and prompt use are essential.

• EZ Cap™ EGFP mRNA (5-moUTP) Assay Guide

  2026-08-12

  A scenario-driven guide to using EZ Cap™ EGFP mRNA (5-moUTP), SKU R1016, to separate transfection and translation effects from cell viability, proliferation, and cytotoxicity measurements. It combines product specifications, practical handling guidance, and recent mRNA/LNP evidence to support more interpretable and reproducible assays.

• ALDH2–APC Synthetic Lethality in Colorectal Cancer

  2026-08-11

  Liang et al. identify aldehyde dehydrogenase 2 (ALDH2) inhibition as a vulnerability of APC-deficient colorectal cancer, linking Disulfiram treatment to ROS accumulation and ASK1/JNK-driven apoptosis. The study provides a genotype-informed framework for cancer research, while also highlighting the need to distinguish ALDH2-dependent effects from Disulfiram’s other biochemical activities.

• Metabolic Sensitization of Ferroptosis and Cuproptosis

  2026-08-11

  The reference study develops a Cu–tannic acid/liposome nanosystem carrying STF-31 to inhibit glycolysis and compensatory NAD+ metabolism, thereby increasing tumor-cell susceptibility to ferroptosis and cuproptosis. Its broader contribution is to connect metabolic depletion, regulated cell death, immunogenic cell death, and tumor immune remodeling in one therapeutic design.

• Functional Metagenomics Reveals Cas9 Inhibitors

  2026-08-10

  Forsberg et al. developed a functional metagenomic selection that identified anti-CRISPR proteins directly from human oral and fecal microbiomes. The study revealed AcrIIA11 as a potent, mechanistically distinct SpyCas9 inhibitor with activity in bacteria and human cells, demonstrating how phenotype-based screening can expand anti-CRISPR discovery beyond sequence annotation.

• CKI 7 Dihydrochloride in CK1 Pathway Studies

  2026-08-09

  CKI 7 dihydrochloride is a Casein kinase 1 inhibitor for dissecting Wnt, circadian, DNA repair, and cancer-associated signaling. This guide presents a causal assay strategy that connects CK1 perturbation with, but does not conflate it with, the MAPK10–KRT16 metastasis axis.

• Glycogen Colorimetric Assay Kit II Workflow

  2026-08-08

  Turn circadian exercise experiments into actionable glycogen data with a practical, interference-aware workflow. The Glycogen Colorimetric Assay Kit II supports sensitive tissue and cell measurements while offering a scalable route from pilot assays to high-throughput metabolic studies.

• Doxycycline-Inducible EMT in MCF10A Cells

  2026-08-07

  Sun, Zhou, and Hu established a reversible doxycycline-inducible Twist1 system that drives epithelial-to-mesenchymal transition in MCF10A mammary epithelial cells. The model provides a controlled alternative to cytokine-induced EMT and a practical platform for testing whether cancer-associated genes influence metastasis through EMT-related mechanisms.

• Rucaparib (AG-014699): Mechanisms and Benchmarks in DNA Repa

  2026-08-07

  Rucaparib (AG-014699) is a highly potent PARP1 inhibitor with a Ki of 1.4 nM, providing a robust research tool for dissecting DNA damage and repair pathways. Its radiosensitization properties are especially pronounced in DNA repair-deficient and prostate cancer cell models. Product-specific data from APExBIO and peer-reviewed studies substantiate its selectivity, cellular effects, and transport dynamics.

• Exendin-4: Rethinking Access and Innovation in Diabetes Rese

  2026-08-06

  Exendin-4 (Exenatide) is at the forefront of next-generation type 2 diabetes research, offering mechanistic precision as a GLP-1 receptor agonist and inspiring new, accessible manufacturing paradigms. This thought-leadership article unpacks the molecular rationale, experimental strategies, and translational possibilities enabled by Exendin-4, including the disruptive potential of yeast-based expression systems. Drawing on recent open-access studies and industry-validated workflows, we frame a strategic vision for translational scientists seeking to improve insulin sensitivity, reverse hepatic steatosis, and scale global access to diabetes therapeutics.

• ATRX Loss Sensitizes Glioma Cells to RTK and PDGFR Inhibitio

  2026-08-06

  The reference study uncovers that ATRX-deficient high-grade glioma cells show increased vulnerability to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors, a finding with significant implications for targeted therapy. Combinatorial treatment with these inhibitors and temozolomide, a standard alkylating agent, markedly enhances cytotoxicity in ATRX-mutant models—highlighting the clinical potential of stratifying patients by ATRX status.

15519 records 1/1035 page Next 12345 下5页 Last page